These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27974416)

  • 1. Metastatic ER+ Breast Cancer's Genomic Landscape.
    Cancer Discov; 2017 Feb; 7(2):OF2. PubMed ID: 27974416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
    Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
    Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1 mutations in breast cancer.
    Dustin D; Gu G; Fuqua SAW
    Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
    Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
    Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Condorelli R; Spring L; O'Shaughnessy J; Lacroix L; Bailleux C; Scott V; Dubois J; Nagy RJ; Lanman RB; Iafrate AJ; Andre F; Bardia A
    Ann Oncol; 2018 Mar; 29(3):640-645. PubMed ID: 29236940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
    Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
    Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
    Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
    Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
    Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
    Angus L; Beije N; Jager A; Martens JW; Sleijfer S
    Cancer Treat Rev; 2017 Jan; 52():33-40. PubMed ID: 27886589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygous retinoblastoma gene mutation compromises in vitro osteogenesis of adipose mesenchymal stem cells - a temporal gene expression study.
    Vincent A; Natarajan V; Khetan V; Krishnakumar S; Parameswaran S
    Exp Cell Res; 2020 Nov; 396(1):112263. PubMed ID: 32890459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative clinical genomics of metastatic cancer.
    Robinson DR; Wu YM; Lonigro RJ; Vats P; Cobain E; Everett J; Cao X; Rabban E; Kumar-Sinha C; Raymond V; Schuetze S; Alva A; Siddiqui J; Chugh R; Worden F; Zalupski MM; Innis J; Mody RJ; Tomlins SA; Lucas D; Baker LH; Ramnath N; Schott AF; Hayes DF; Vijai J; Offit K; Stoffel EM; Roberts JS; Smith DC; Kunju LP; Talpaz M; Cieślik M; Chinnaiyan AM
    Nature; 2017 Aug; 548(7667):297-303. PubMed ID: 28783718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.
    Kooi IE; Mol BM; Massink MP; Ameziane N; Meijers-Heijboer H; Dommering CJ; van Mil SE; de Vries Y; van der Hout AH; Kaspers GJ; Moll AC; Te Riele H; Cloos J; Dorsman JC
    Sci Rep; 2016 Apr; 6():25264. PubMed ID: 27126562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.